🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Just in The Oncologist: In a large cohort of Black men with advanced #prostatecancer undergoing ctDNA profiling 👉Machine learning analysis shows ⬆️ frequency of AR, EGFR, MYC, FGFR1, CTNNB1 alterations in Black vs. White men👇bit.ly/3wHKRcM OncoAlert Pedro C Barata, MD MSc FACP Mehmet Asim Bilen,MD

In this commentary, Max Smith & @WilliamFigg1 discuss a recently published trial on #COMT genotype and #opioid dose requirements. They describe the current evidence & resources for opioid pharmacogenetic testing to improve #pain management. #PGx doi.org/10.1093/oncolo…

A recent meta-analysis including 13,929 patients in The Oncologist also supported routine genotyping The Oncologist academic.oup.com/oncolo/article… Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy....... Sharma et al.

Our terrific CTR editor at The Oncologist! The Oncologist

🔘In this retrospective study No increase in renal or non-renal immune-related side effects with immunotherapy in patients with stage 4-5 CKD (eGFR<30), which is usually the exclusion criterion in clinical trials The Oncologist OncoAlert #MedTwitter ASCO doi.org/10.1093/oncolo…

An article from the February issue of The Oncologist reports on whether differences in patients’ race/ethnicity, preferred language, and other factors are associated with patient enrollment in oncology research studies. buff.ly/3m2Ayhd

Important commentary on future directions in ctDNA assessment. May be an approach to identifying cancers with epigenetic origins. The Oncologist

I am amazed & thrilled to have been selected for this important award, and am looking forward to being in Paris for the 2023 ESMO TAT meeting -- by my count it is TAT #20. Thank you ESMO! #ESMOTAT23

Please all send us examples of PD1/L1 post PD/L1 failures from randomized trials where same control backbone in both arms. We need the help of the oncology community ! Thank you Oncology Brothers OncoAlert ASCO ESMO - Eur. Oncology Melanoma Research Foundation SWOG Cancer Research Network Alliance for Clinical Trials in Oncology ECOG-ACRIN Cancer Research Group NCICancerTrials

Congratulations to Susan Bates, MD, who has received the 2023 ESMO (ESMO - Eur. Oncology) Targeted Anticancer Therapies Honorary Award, recognizing her significant contributions to the field of anticancer drug development. 👏 Dr. Bates presents her award lecture today at #ESMOTAT23.

Patients are the greatest educators. Every interaction with them is a learning experience. Let's continue to learn from their strength, resilience, and unique perspectives. #patientexperience #education OncoAlert CancerDotNet Sumanta K. Pal, MD, FASCO Toni Choueiri, MD ASCO ESMO - Eur. Oncology Kidney Cancer

Older Patients Are Comfortable With Telehealth and Prefer It as an Option - 92% of those over 70 say they are comfortable with telehealth. buff.ly/3mLB7fU

Agree completely. Words matter, and "fail treatment" inevitably implies, however unintended, that the patient is somehow at fault. The Oncologist

📚 🔬 Thrilled to share a new EORTC publication on The Oncologist: "#QualityOfLife in Male #BreastCancer: Prospective Study of the International #MaleBreastCancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG)" 👉 doi.org/10.1093/oncolo… #CancerResearch #ClinicalTrials #Oncology

Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World Study buff.ly/3EJmEGI

Unraveling the Link: MUTYH mutations drive higher KRAS G12C prevalence, heightened tumor mutational burden, and unique mutational signatures across cancers. Fred R. Hirsch #MolecularBiology #Research doi.org/10.1093/oncolo…

Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials - via The Oncologist. academic.oup.com/oncolo/advance… #OCEPublications

OCE's Gautam Mehta, MD and colleagues summarize the FDA accelerated approval of fam-trastuzumab deruxtecan-nxki—the first targeted treatment option for patients with HER2-mutated non-small cell lung cancer - via The Oncologist academic.oup.com/oncolo/advance… #OCEPublications #lcsm #NSCLC